全身型若年性特発性関節炎市場- 世界の産業規模、シェア、動向、機会、予測、治療タイプ別、投与経路別、流通チャネル別、地域別、競合別セグメント、2020-2030F

全身型若年性特発性関節炎（sJIA）の世界市場は、2024年に18億3,000万米ドルと評価され、予測期間中に4.61％の複合年間成長率（CAGR）を記録し、2030年までに24億米ドルに達すると予測されています。

この市場は、若年性特発性関節炎の希少かつ重篤なサブタイプである全身性JIAの開発、診断、治療、管理を包括しています。

sJIAは、主に小児が罹患する複雑な自己免疫疾患であり、全身性の炎症、高熱、皮疹、関節痛を特徴とし、臓器障害を含む合併症の可能性があります。同市場は、患者の転帰とQOLの改善を目的とした医薬品、生物学的製剤、医療機器、支持療法戦略など、広範な治療ソリューションに及んでいます。

主な市場促進要因

生物学的製剤の進歩

主な市場課題

高い治療費

主な市場動向

個別化医療

目次

第1章 概要

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 顧客の声

第5章 世界の全身型若年性特発性関節炎市場展望

• 市場規模・予測
  • 金額別
• 市場シェア・予測
  • 治療の種類別（薬物治療（抗炎症薬（NSAID）、腫瘍壊死因子（TNF）阻害剤、筋弛緩薬、免疫抑制薬、疾患修飾性抗リウマチ薬、その他）、生物学的製剤、その他）
  • 投与経路別（経口、注射、その他）
  • 流通チャネル別（病院薬局、小売薬局、オンライン薬局）
  • 企業別（2024）
  • 地域別
• 市場マップ

第6章 北米の全身型若年性特発性関節炎市場展望

• 市場規模・予測
• 市場シェア・予測
• 北米：国別分析
  • 米国
  • メキシコ
  • カナダ

第7章 欧州の全身型若年性特発性関節炎市場展望

• 市場規模・予測
• 市場シェア・予測
• 欧州：国別分析
  • フランス
  • ドイツ
  • 英国
  • イタリア
  • スペイン

第8章 アジア太平洋地域の全身型若年性特発性関節炎市場展望

• 市場規模・予測
• 市場シェア・予測
• アジア太平洋地域：国別分析
  • 中国
  • インド
  • 韓国
  • 日本
  • オーストラリア

第9章 南米の全身型若年性特発性関節炎市場展望

• 市場規模・予測
• 市場シェア・予測
• 南米：国別分析
  • ブラジル
  • アルゼンチン
  • コロンビア

第10章 中東・アフリカの全身型若年性特発性関節炎市場展望

• 市場規模・予測
• 市場シェア・予測
• 中東・アフリカ：国別分析
  • 南アフリカ
  • サウジアラビア
  • アラブ首長国連邦

第11章 市場力学

• 促進要因
• 課題

第12章 市場動向と発展

• 最近の動向
• 製品上市
• 合併と買収

第13章 PESTEL分析

第14章 ポーターのファイブフォース分析

• 業界内の競合
• 新規参入の可能性
• サプライヤーの力
• 顧客の力
• 代替品の脅威

第15章 競合情勢

• Novartis AG
• Hoffmann-La Roche Ltd
• Takeda Pharmaceutical Company Limited
• Bristol-Myers Squibb Company
• Cadila Healthcare Ltd.
• Genetech, Inc.
• LATAM Pharma
• Alteogen Inc.
• Johnson & Johnson
• Momenta Pharmaceuticals, Inc.

第16章 戦略的提言

第17章 調査会社について・免責事項

Global Systemic Juvenile Idiopathic Arthritis (sJIA) Market was valued at USD 1.83 billion in 2024 and is projected to reach USD 2.40 billion by 2030, registering a compound annual growth rate (CAGR) of 4.61% during the forecast period. This market encompasses the development, diagnosis, treatment, and management of systemic JIA-a rare and severe subtype of juvenile idiopathic arthritis.

sJIA is a complex autoimmune condition primarily affecting children and is marked by systemic inflammation, high fevers, skin rashes, and joint pain, with potential complications including organ damage. The market spans a broad spectrum of therapeutic solutions, including pharmaceuticals, biologics, medical devices, and supportive care strategies aimed at improving patient outcomes and quality of life.

Key Market Drivers

Advancements in Biologic Therapies

The increasing global burden of chronic autoimmune diseases is a key contributor to the growth of the sJIA market. Although systemic JIA is a rare pediatric autoimmune condition, it benefits from broader developments in autoimmune disease research and treatment.

According to a study published in Frontiers in Immunology (PMC9918670), the incidence of autoimmune diseases has increased by 19.1%, with a 12.5% rise in prevalence annually. This trend has intensified global focus and investment in autoimmune research, accelerating the development of new treatment approaches for conditions such as sJIA.

Research into more common autoimmune disorders-such as lupus and rheumatoid arthritis-has uncovered shared immunological pathways that are informing the development of novel and repurposed therapies for sJIA. Healthcare systems are also shifting toward integrated, patient-centered chronic disease management models, prioritizing early diagnosis, personalized care plans, and coordinated treatment approaches.

In the United States, the CDC reports that approximately 220,000 children and adolescents live with arthritis-related conditions, including sJIA (MMWR Morb Mortal Wkly Rep 2023;72:793-798). This growing pediatric population is prompting improved screening and referral systems, which in turn are enhancing early detection and treatment outcomes.

Pharmaceutical companies are responding to this demand by investing heavily in biologics and other targeted therapies specifically designed for pediatric autoimmune conditions. These innovations are reshaping the treatment landscape, improving clinical outcomes, and enhancing quality of life for affected children.

Key Market Challenges

High Treatment Costs

One of the most significant barriers to effective care in the Global sJIA Market is the high cost associated with treatment. Managing sJIA typically involves a comprehensive, multidisciplinary approach, including medications to control systemic inflammation and prevent long-term complications.

A major cost driver is the use of biologic therapies, particularly IL-1 and IL-6 inhibitors, which have proven highly effective in treating sJIA. However, these advanced biologics are among the most expensive drugs on the market and often require long-term administration, leading to a substantial financial burden for patients and healthcare systems.

Beyond the cost of medications, managing sJIA often involves routine monitoring, imaging studies, physical therapy, and consultations with multiple specialists. These ancillary costs can further strain healthcare budgets and impose significant financial challenges on families.

Key Market Trends

Personalized Medicine

Personalized medicine is increasingly shaping the future of the sJIA market by offering more tailored and effective treatment approaches based on an individual's genetic, molecular, and clinical profile. This patient-specific strategy is helping optimize therapeutic outcomes while reducing risks associated with traditional trial-and-error treatment methods.

In sJIA care, the use of advanced molecular and genetic profiling tools enables clinicians to better understand disease mechanisms and identify actionable molecular targets. This facilitates the development of highly specialized treatment plans that address the unique disease pathways of each patient.

A key advantage of personalized medicine is its predictive capability-allowing healthcare providers to determine which patients are most likely to respond favorably to specific biologics or immunosuppressive therapies. This not only enhances treatment efficacy but also reduces exposure to ineffective medications and associated side effects.

Furthermore, personalized dosing strategies ensure that patients receive the most appropriate therapeutic regimen, enhancing treatment safety and improving overall patient outcomes. As this approach becomes more widely adopted, it is expected to significantly advance the management of sJIA and reinforce the market's growth trajectory.

Key Market Players

• Novartis AG
• Hoffmann-La Roche Ltd
• Takeda Pharmaceutical Company Limited
• Bristol - Myers Squibb Company
• Cadila Healthcare Ltd.
• Genetech, Inc.
• LATAM Pharma
• Alteogen Inc.
• Johnson & Johnson
• Momenta Pharmaceuticals, Inc

Report Scope:

In this report, the Global Systemic Juvenile Idiopathic Arthritis Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Global Systemic Juvenile Idiopathic Arthritis Market, By Treatment Type:

• Drug Treatment
• Biologics
• Other

Global Systemic Juvenile Idiopathic Arthritis Market, By Route of Administration:

• Oral
• Injectables
• Other

Global Systemic Juvenile Idiopathic Arthritis Market, By Distribution Channel:

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

Global Systemic Juvenile Idiopathic Arthritis Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Systemic Juvenile Idiopathic Arthritis Market.

Available Customizations:

Global Systemic Juvenile Idiopathic Arthritis Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Systemic Juvenile Idiopathic Arthritis Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Treatment Type (Drug Treatment {Anti-inflammatories (NSAIDS), Tumor Necrosis Factor (TNF) Blockers, Muscle Relaxants, Immune Suppressants Drugs, Disease Modifying Antirheumatic Drugs, Others}, Biologics, Other)
  • 5.2.2. By Route of Administration (Oral, Injectables, Other)
  • 5.2.3. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)
  • 5.2.4. By Company (2024)
  • 5.2.5. By Region
• 5.3. Market Map

6. North America Systemic Juvenile Idiopathic Arthritis Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Treatment Type
  • 6.2.2. By Route of Administration
  • 6.2.3. By Distribution Channel
  • 6.2.4. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Systemic Juvenile Idiopathic Arthritis Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Treatment Type
      • 6.3.1.2.2. By Route of Administration
      • 6.3.1.2.3. By Distribution Channel
  • 6.3.2. Mexico Systemic Juvenile Idiopathic Arthritis Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Treatment Type
      • 6.3.2.2.2. By Route of Administration
      • 6.3.2.2.3. By Distribution Channel
  • 6.3.3. Canada Systemic Juvenile Idiopathic Arthritis Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Treatment Type
      • 6.3.3.2.2. By Route of Administration
      • 6.3.3.2.3. By Distribution Channel

7. Europe Systemic Juvenile Idiopathic Arthritis Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Treatment Type
  • 7.2.2. By Route of Administration
  • 7.2.3. By Distribution Channel
  • 7.2.4. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. France Systemic Juvenile Idiopathic Arthritis Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Treatment Type
      • 7.3.1.2.2. By Route of Administration
      • 7.3.1.2.3. By Distribution Channel
  • 7.3.2. Germany Systemic Juvenile Idiopathic Arthritis Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Treatment Type
      • 7.3.2.2.2. By Route of Administration
      • 7.3.2.2.3. By Distribution Channel
  • 7.3.3. United Kingdom Systemic Juvenile Idiopathic Arthritis Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Treatment Type
      • 7.3.3.2.2. By Route of Administration
      • 7.3.3.2.3. By Distribution Channel
  • 7.3.4. Italy Systemic Juvenile Idiopathic Arthritis Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Treatment Type
      • 7.3.4.2.2. By Route of Administration
      • 7.3.4.2.3. By Distribution Channel
  • 7.3.5. Spain Systemic Juvenile Idiopathic Arthritis Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Treatment Type
      • 7.3.5.2.2. By Route of Administration
      • 7.3.5.2.3. By Distribution Channel

8. Asia-Pacific Systemic Juvenile Idiopathic Arthritis Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Treatment Type
  • 8.2.2. By Route of Administration
  • 8.2.3. By Distribution Channel
  • 8.2.4. By Country
• 8.3. Asia-Pacific: Country Analysis
  • 8.3.1. China Systemic Juvenile Idiopathic Arthritis Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Treatment Type
      • 8.3.1.2.2. By Route of Administration
      • 8.3.1.2.3. By Distribution Channel
  • 8.3.2. India Systemic Juvenile Idiopathic Arthritis Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Treatment Type
      • 8.3.2.2.2. By Route of Administration
      • 8.3.2.2.3. By Distribution Channel
  • 8.3.3. South Korea Systemic Juvenile Idiopathic Arthritis Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Treatment Type
      • 8.3.3.2.2. By Route of Administration
      • 8.3.3.2.3. By Distribution Channel
  • 8.3.4. Japan Systemic Juvenile Idiopathic Arthritis Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Treatment Type
      • 8.3.4.2.2. By Route of Administration
      • 8.3.4.2.3. By Distribution Channel
  • 8.3.5. Australia Systemic Juvenile Idiopathic Arthritis Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Treatment Type
      • 8.3.5.2.2. By Route of Administration
      • 8.3.5.2.3. By Distribution Channel

9. South America Systemic Juvenile Idiopathic Arthritis Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Treatment Type
  • 9.2.2. By Route of Administration
  • 9.2.3. By Distribution Channel
  • 9.2.4. By Country
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil Systemic Juvenile Idiopathic Arthritis Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Treatment Type
      • 9.3.1.2.2. By Route of Administration
      • 9.3.1.2.3. By Distribution Channel
  • 9.3.2. Argentina Systemic Juvenile Idiopathic Arthritis Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Treatment Type
      • 9.3.2.2.2. By Route of Administration
      • 9.3.2.2.3. By Distribution Channel
  • 9.3.3. Colombia Systemic Juvenile Idiopathic Arthritis Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Treatment Type
      • 9.3.3.2.2. By Route of Administration
      • 9.3.3.2.3. By Distribution Channel

10. Middle East and Africa Systemic Juvenile Idiopathic Arthritis Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Treatment Type
  • 10.2.2. By Route of Administration
  • 10.2.3. By Distribution Channel
  • 10.2.4. By Country
• 10.3. MEA: Country Analysis
  • 10.3.1. South Africa Systemic Juvenile Idiopathic Arthritis Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Treatment Type
      • 10.3.1.2.2. By Route of Administration
      • 10.3.1.2.3. By Distribution Channel
  • 10.3.2. Saudi Arabia Systemic Juvenile Idiopathic Arthritis Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Treatment Type
      • 10.3.2.2.2. By Route of Administration
      • 10.3.2.2.3. By Distribution Channel
  • 10.3.3. UAE Systemic Juvenile Idiopathic Arthritis Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Treatment Type
      • 10.3.3.2.2. By Route of Administration
      • 10.3.3.2.3. By Distribution Channel

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Recent Developments
• 12.2. Product Launches
• 12.3. Mergers & Acquisitions

13. PESTLE Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Product

15. Competitive Landscape

• 15.1. Novartis AG
  • 15.1.1. Business Overview
  • 15.1.2. Company Snapshot
  • 15.1.3. Products & Services
  • 15.1.4. Financials (In case of listed companies)
  • 15.1.5. Recent Developments
  • 15.1.6. SWOT Analysis
• 15.2. Hoffmann-La Roche Ltd
• 15.3. Takeda Pharmaceutical Company Limited
• 15.4. Bristol - Myers Squibb Company
• 15.5. Cadila Healthcare Ltd.
• 15.6. Genetech, Inc.
• 15.7. LATAM Pharma
• 15.8. Alteogen Inc.
• 15.9. Johnson & Johnson
• 15.10. Momenta Pharmaceuticals, Inc.

16. Strategic Recommendations

17. About Us & Disclaimer